This protocol applies to patients with suspected or confirmed advanced-stage epithelial ovarian, fallopian tube, or primary peritoneal cancer who were identified as confirmed poor surgical candidates — or who had a low likelihood of achieving optimal cytoreduction — and who have completed an initial course of neoadjuvant chemotherapy.
Patients in this setting present with advanced-stage disease not suitable for primary debulking surgery, either due to poor performance status or because achieving optimal cytoreduction at initial presentation was considered unlikely. Neoadjuvant chemotherapy with a platinum-based regimen is used to reduce tumor burden ahead of a planned surgical step.
The preceding phase involved neoadjuvant therapy using a platinum-based regimen. The clinical target of that phase was to achieve response or disease stabilisation — a sufficient reduction in tumor burden — to make interval debulking surgery feasible. Once that surgical threshold is reached, this protocol defines the next step.
After completing neoadjuvant chemotherapy, surgical intervention — interval debulking surgery — becomes the focus, with the goal of achieving complete removal of gross disease from the abdomen, pelvis, and retroperitoneum. For certain patients, an additional intraperitoneal treatment may also be considered at the time of surgery. The complete structured regimen, including full eligibility criteria and sequencing, is available via the link below.